EmeraNova Launches Catalyst Accelerator to Advance Startups in Tissue Restoration and Advanced Wound Care EmeraNova™, a Phoenix-based medical technology company specializing in advanced tissue restoration technologies, has launched Catalyst, a…
Global Healthy Living Foundation to Present Six Patient-Centered Research Abstracts at ACR Convergence 2026, Highlighting Myositis and PMR Research The Global Healthy Living Foundation (GHLF) has announced that it will…
Polaris Rx Selected by Bristol Myers Squibb to Dispense First-in-Class Multiple Myeloma Therapy ZENBEXUS (Iberdomide) Polaris Rx has announced that it has been selected by Bristol Myers Squibb (BMS) to…
Penn-BioNTech Innovative Therapeutics Seed Fund Reveals Its First Investment to Advance Therapeutic Innovation The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) has announced its investment in Emvena Therapeutics, a biotechnology…
BeOne Medicines Receives FDA Priority Review for BRUKINSA Plus Rituximab in Previously Untreated Mantle Cell Lymphoma BeOne Medicines Ltd., a global oncology company focused on developing innovative cancer treatments, has…
Immunome to Present Promising Initial Phase 1 Clinical Results for ROR1-Targeted ADC IM-1021 in Advanced B-Cell Lymphomas at ASH 2026 Immunome, Inc., a clinical-stage targeted oncology company focused on developing…
BioLife Products to Showcase Patented Oral Peptide Delivery Technology at London Life Sciences Week 2026 BioLife Products Limited will present its patented oral peptide delivery technology and recent intellectual property…
Sun Nuclear Launches Simon Cloud-Based Platform to Monitor Linear Accelerator Health and Strengthen Radiation Therapy Quality Assurance Sun Nuclear, a Mirion Medical company, has announced the global launch of Simon™,…
Mirum Pharmaceuticals Reports Strong Third-Quarter 2026 Results, Raises Full-Year Sales Guidance and Advances Rare Disease Pipeline Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing treatments for rare…
Imperative Care Reports Comparable Outcomes in Women and Men Following Symphony Thrombectomy for Intermediate-Risk Pulmonary Embolism Imperative Care, a medical technology company focused on advancing the treatment of thromboembolic disease,…
Ropeginterferon Alfa-2b Gains ET Approvals Across Major Global Markets, Broadening Treatment Access for Patients PharmaEssentia Corporation’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), is expanding its presence in the global market…
City of Hope and Collaborators Report Promising Phase 1 Results for SER-155, a 16-Strain Live Biotherapeutic Designed to Prevent Bloodstream Infections in Stem Cell Transplant Patients City of Hope®, one…